Enter your search



Celnova Pharma today announced that it has entered into an exclusive distribution agreement with Laboratoire Aguettant of France to commercialize APOKINON® (apomorphine self-injection pen) in the Argentine market. APOKINON® will be part of Celnova Pharma’s growing Central Nervous System portfolio.

Under the new agreement, Celnova Pharma will be responsible for marketing authorizations, market access, commercialization and distribution in Argentina.

“We are excited to initiate this partnership with Aguettant, a leading European pharmaceutical company, in order to maximize the availability of APOKINON® in Argentina” said Juan Marrone, founder and CEO of Celnova Pharma. “This agreement will assure an uninterrupted supply of APOKINON®, the only available therapeutic option in Argentina to treat off episodes in people with advanced Parkinson’s disease”.

“We strongly believe that Celnova Pharma is the best choice to ensure a guaranteed coverage of Apokinon® for Argentina’s patients. Moreover, we are truly enthusiastic to build the future of our products in Argentina, by bringing more Apokinon® presentations and forms to the patients and offer them a wider therapeutic scope with Celnova Pharma’s expertise.” said Laurent Coveliers, International Senior Director at Laboratoire Aguettant.

About Celnova Pharma

Celnova Pharma is a pharmaceutical company focused in complex therapeutic classes such as oncology, central nervous system and critical care. Celnova has established operations in Argentina and Chile, and is in the process of opening its Peru and Colombia subsidiaries.

Celnova’s business model combines branded generics with in-licensing of established drugs from multinational companies and patent-protected unique drugs.

Celnova’s long term goal is to grow in Latin America through a mix of organic growth and selected partnerships and acquisitions. For more information, please visit www.celnova.com.

Celnova Pharma is a registered trademark of Celnova Argentina S.A.

About Aguettant

Laboratoire Aguettant SAS is a pharmaceutical company dedicated to the development, manufacturing and commercialization of essential hospital medicines. Its expertise in developing innovative injectable drugs makes Aguettant a duly recognized player in critical care, anesthesiology, micronutrients and neurology. The company has a strong commercial infrastructure in Europe through its subsidiaries and elsewhere in the world through its international distributors.